Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
38.57 USD | +0.29% | -0.18% | +4.36% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 58% by 2026.
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- The company has a low valuation given the cash flows generated by its activity.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- The opinion of analysts covering the stock has improved over the past four months.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Weaknesses
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+4.36% | 4.9B | A- | ||
-2.31% | 103B | B+ | ||
+0.56% | 95.28B | B+ | ||
+1.69% | 22.15B | B | ||
-17.37% | 21.02B | B+ | ||
-9.30% | 18.15B | A- | ||
-41.01% | 16.73B | A- | ||
-14.85% | 16.05B | B | ||
+3.21% | 13.68B | C+ | ||
+33.54% | 12.17B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- HALO Stock
- Ratings Halozyme Therapeutics, Inc.